Transforming growth factor-b (TGFb) modulates the expression of multiple apoptotic target genes; however, a common and central signaling pathway, acting downstream of TGFb and leading to cell death, has yet to be uncovered. Here, we show that TGFb-induced apoptosis in cancer cells requires the transcription factor E2F1 (E2 promoter-binding factor 1). Using the E2F1 knockout mouse model, we also found E2F1 to be required for TGFb-mediated apoptosis in normal cells. Moreover, we found TGFb to increase E2F1 protein stability, acting at the post-translational level. We further investigated the molecular mechanisms by which E2F1 contributes to TGFb-mediated apoptosis and found that TGFb treatment led to the formation of a transcriptionally active E2F1-pRb-P/CAF complex on multiple TGFb pro-apoptotic target gene promoters, thereby activating their transcription. Together, our findings define a novel process of gene activation by the TGFb-E2F1 signaling axis and highlight E2F1 as a central mediator of the TGFb apoptotic program.
Subject Category: Cancer
Transforming growth factor-b (TGFb) and its related family members are involved in the regulation of a wide range of fundamental cellular processes, including the regulation of growth, differentiation, and apoptosis. 1 TGFb, the prototype of the family, is a vital factor in the maintenance of homeostasis between cell growth and apoptosis. TGFb exerts its tumor-suppressive effects by inhibiting cell-cycle progression, inducing apoptosis, and preventing immortalization through inhibition of telomerase activity. Loss or mutation of TGFb signaling components is frequently observed in human cancer and further define a tumor-suppressive role for this growth factor. 2 TGFb ligands signal through serine/threonine kinase receptors that, once activated by ligand binding, recruit and phosphorylate the canonical downstream mediators, Smad2 and Smad3. Once phosphorylated, Smad2 and Smad3 interact with Smad4 to then translocate to the nucleus where the Smad complex associates with diverse DNA-binding factors to regulate expression of target genes in a cell-and tissue-specific manner. These partner proteins, which act as co-activators or co-repressors, are differentially expressed in different cell types and are thus thought to provide a basis for tissue and cell type-specific functions for TGFb ligands. 3 TGFb induces a number of apoptotic responses and its ability to do so varies greatly depending on the cell type. 4 Understanding the basis of this variability requires elucidating the molecular mechanisms involved in regulating TGFb-mediated apoptosis. TGFb signaling activates caspases in various epithelial cell types 5, 6 and transcriptionally induces DAPK (death-associated protein kinase) in hepatoma cells. 7 TGFb also induces apoptosis by antagonizing PI3K (phosphatidylinositol 3-kinase)/Akt signaling activity through expression of the lipid phosphatase SHIP (SH2-domain-containing inositol-5-phosphatase) in hematopoietic cells. 8 Transcriptional up-regulation of pro-apoptotic proteins such as Bax (Bcl-2-associated X protein) and downregulation of pro-survival Bcl-2 (B-cell lymphoma 2) family members have also been implicated in TGFb-mediated programmed cell death. 9, 10 However, these mechanisms are context and tissue-specific; a central mechanism acting downstream of TGFb to induce apoptosis has not yet been described.
We previously demonstrated that the TGFb inhibitory effect on telomerase activity and cell immortalization is dependent on both Smad3 and the transcription factor E2F1 (E2 promoter-binding factor 1), highlighting E2F1 as an important mediator of TGFb tumor-suppressive effects. 11 The E2F family of transcription factors is a group of DNA-binding proteins that are central regulators of cell-cycle progression. The transcriptional activity of E2F1-5 is regulated primarily via their association with members of the retinoblastoma family of pocket proteins, which include pRb (retinoblastoma tumorsuppressor protein)/p105, p107, and p130.
12 E2F1, the founding member and best-characterized of the family, has a unique role compared with other E2Fs, showing characteristics of being both an oncogene and a tumor suppressor, as it is able to induce both cell-cycle progression and apoptosis. Though an increase in E2F1 activity has been reported in several types of tumors 13, 14 supporting an oncogenic role for E2F1, transgenic mice overexpressing E2F1 display aberrant cell apoptosis. 15 Furthermore, E2F1 knockout mice develop highly malignant tumors and show defects in thymocyte apoptosis, highlighting E2F1 as a potent tumor suppressor. 16 The nature of this dichotomy is proposed to be based on the degree to which E2F1 is expressed in the context of the cell cycle and/or following DNA damage, and the notion that different threshold levels of E2F1 are required for differential transactivation of its target gene promoters, which may favor either survival or apoptosis. 17 Interestingly, E2F1 mutants that are unable to promote cell-cycle progression retain their ability to induce programmed cell death, indicating that induction of the cell cycle and apoptosis are separable functions of E2F1. 18 Given our previous findings that E2F1 is required for TGFb-mediated inhibition of hTERT (human telomerase reverse transcriptase) 11 and that TGFb promotes increased E2F-DNA-binding activity in pre-apoptotic hepatoma cell nuclear extracts, 19 we investigated whether E2F1 could also mediate another arm of the TGFb tumor-suppressive response and regulate apoptosis.
We found TGFb to regulate the transcription of a number of pro-apoptotic genes in an E2F1-dependent manner in cancer cell lines from various tissues. Using embryonic fibroblasts from the E2F1 knockout mouse model, we also found E2F1 to be required for TGFb-mediated apoptosis in normal cells. Moreover, we found TGFb to increase E2F1 protein stability, acting post-translationally. We further investigated the molecular mechanisms by which E2F1 contributes to TGFbmediated cell death and found that TGFb could promote formation of a transcriptionally active E2F1-pRb-P/CAF (p300/CREB-binding protein-associated factor) complex onto the promoters of TGFb-targeted apoptotic genes to activate their transcription. Together, our results underline E2F1 as a central mediator of the TGFb pro-apoptotic response and highlight the E2F1-pRb-P/CAF signaling pathway as a critical regulator of TGFb-mediated cell death.
Results
TGFb-mediated apoptosis is dependent on E2F1. We first examined the pro-apoptotic effect of TGFb in various model systems, including two human hepatoma cell lines (HuH7 and HepG2), a human melanoma cell line (WM278), and a human keratinocyte cell line (HaCaT). Cells were stimulated or not with TGFb as indicated and apoptosis was assessed using MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) cell viability assay as well as calcein-AM (calcein-acetoxymethyl ester) assay, a more sensitive assay for early apoptosis detection. 20 All cell lines tested were strongly growth inhibited by TGFb treatment in a time-dependent manner (Figures 1a and b) . To address the contribution of E2F1 in mediating this TGFb response, we used RNA interference to reduce the expression of endogenous E2F1. Interestingly, we found that the effect of TGFb on cell viability ( Figure 1c ) and early apoptosis (Figure 1d ) in all the cell lines tested was almost completely prevented when E2F1 expression was silenced, indicating that E2F1 is required for mediating the TGFb pro-apoptotic response in multiple cell lines of various origins.
To further investigate the role of E2F1 in TGFb-mediated apoptosis, we performed fluorescence-activated cell sorting (FACS) following AnnexinV and propidium iodide staining. Although TGFb treatment markedly increased the number of apoptotic cells in control siRNA-transfected HuH7 cells (Figure 1f , left panels), E2F1 knockdown completely abolished this effect (Figure 1f , right panels), consistent with cell viability and calcein-AM results. Fluorescence imaging following AnnexinV staining further confirmed these findings ( Figure 1g ). Taken together, these results indicate that TGFb has a strong pro-apoptotic function in various cell lines and that these effects require the transcription factor E2F1.
E2F1 is required for TGFb-mediated regulation of pro-apoptotic target genes. TGFb signaling activates multiple pro-apoptotic genes and pathways in a cell-and tissuespecific manner. 4 Independently of TGFb, the E2F pathway is also involved in multiple distinct apoptotic mechanisms. In varying cell types and tissues, E2F1 alone has been shown to activate numerous pro-apoptotic genes, including Apaf1 (apoptotic protease activating factor 1), p14ARF, p73, Caspase 3, Caspase 7, Caspase 8, Chk2 (checkpoint kinase 2), Ask-1 (apoptosis signal-regulating kinase 1), and Smac/ DIABLO (second mitochondrial-derived activator of caspase/ direct IAP-binding protein with low pI). [21] [22] [23] [24] [25] [26] [27] To assess whether TGFb and E2F1 share any common downstream apoptotic targets, we examined the regulation of representative E2F1-responsive pro-apoptotic genes in TGFb-treated human hepatoma HuH7 cells, which express both functional p53 and pRb. As shown in Figure 2a , TGFb potently induced mRNA expression of Apaf1, Caspase 3, Caspase 7, p73, and Smac/DIABLO, suggesting that TGFb induces apoptosis in HuH7 cells by the intrinsic mitochondrial pathway. Importantly, this analysis also revealed Smac/ DIABLO as a novel TGFb target. Loss of E2F1 expression markedly impaired the TGFb-mediated induction of each of these target genes (Figure 2b ), indicating that E2F1 is required for TGFb-mediated regulation of its pro-apoptotic downstream target genes. Moreover, these data provide a novel pathway by which TGFb regulates these genes and reveals E2F1 as a widespread co-transducer of TGFbinduced activation of the intrinsic mitochondrial pathway.
To then examine whether these pro-apoptotic genes are direct targets of TGFb, cells were treated or not with the TGFb-mediated cell death requires pRb-E2F1-P/CAF J Korah et al translational inhibitor cycloheximide (CHX) and stimulated with TGFb as indicated. Interestingly, CHX treatment of the cells completely impaired the induction of these genes by TGFb ( Figure 2c ). As a control, the mRNA expression levels of a direct TGFb target gene, Smad7, were also examined and, as expected, were not affected by CHX treatment. These results indicate that TGFb regulation of expression of its downstream pro-apoptotic target genes is indirect and requires the induction of a TGFb-responsive transcriptional activator.
TGFb rapidly and transiently induces E2F1 protein expression levels. Having shown that TGFb indirectly induces the expression of these pro-apoptotic target genes and that E2F1 is required for this process, we next sought to determine whether E2F1 expression itself was regulated by TGFb. TGFb treatment induced a time-dependent decrease in E2F1 mRNA levels in HaCaT cells (Figure 3a ), in agreement with previous reports. 28, 29 Surprisingly, however, we found TGFb to rapidly and transiently induce E2F1 protein expression levels in these cells (Figure 3b ). We then examined the TGFb effect on E2F1 protein expression levels in human epithelial cancer cell lines originating from different tissues (melanoma, hepatocarcinoma, and colon carcinoma) and, as shown in Figure 3c , E2F1 protein levels were strongly induced by TGFb in all the cell lines tested. This effect was transient, however, as longer exposure to TGFb resulted in a return to basal E2F1 protein levels. Interestingly, in all cases the increase in E2F1 expression in response to TGFb was very rapid, suggesting that TGFb induces posttranslational protein stabilization of E2F1. To address this, we performed a CHX chase in HaCaT cells treated or not with TGFb (Figure 3d ). In the presence of CHX, untreated cells showed progressive diminished levels of E2F1 over time. Conversely, TGFb treatment maintained E2F1 levels throughout the chase, indicating that TGFb indeed prolongs E2F1 half-life, by stabilizing E2F1 protein levels posttranslationally.
TGFb pro-apoptotic effects are impaired in E2F1-null embryonic fibroblasts. Having shown that TGFb-induced apoptosis in various epithelial cancer cell lines requires E2F1, we next examined the contribution of E2F1 downstream of TGFb-mediated cell death in normal cells. For this, we used mouse embryonic fibroblasts (MEFs) isolated from wild-type and E2F1-deficient mice. Importantly, both wildtype (E2F1 þ / þ ) and E2F1-null (E2F1 À / À ) MEFs respond equally to TGFb stimulation, as assessed by the induction of Smad phosphorylation (Figure 4a ). The pro-apoptotic effect of TGFb, however, greatly differed in these two cell types. Athough cell viability of the wild-type E2F1 þ / þ MEFs was potently decreased in response to TGFb, this effect was severely impaired in the E2F1 À / À MEFs (Figure 4b ). Correspondingly, TGFb-induced expression of Caspase 7 and Smac/DIABLO was significantly reduced in the E2F1 À / À MEFs (Figure 4c ). Together, these findings highlight a critical role for E2F1 downstream of TGFb in the mediation of apoptosis in a normal cell setting in addition to multiple cell lines of various cancer origins.
E2F1 DNA-binding, transactivation, and pRb-interaction are required for TGFb-mediated apoptosis. To further understand the molecular mechanisms underlying the role of E2F1 in the induction of programmed cell death by TGFb, we next addressed the contribution of E2F1's principal regulator, pRb. For this, we used dominant-negative E2F1 mutant forms to alter E2F1 function and/or binding to pRb. Importantly, the DNA-binding-deficient mutant, E2F1 (E132), and the transactivation-defective mutant, E2F1 (1-374), are both reportedly unable to activate transcription, whereas the E2F1 Y411C mutant, which has lost its ability to interact with pRb, retains similar transcriptional-activating potential as its wild-type E2F1. 30 Interestingly, transient overexpression of each of these mutants drastically impeded the effect of TGFb on cell viability in HuH7 cells (Figure 5a ). The antagonistic effects of these E2F1 mutants were further established at the transcriptional level, as their overexpression significantly reduced TGFb-induced Caspase 7 and Smac/DIABLO mRNA levels (Figure 5b ). These results indicate that TGFb requires not only proper E2F1 function (DNA binding and transactivation), but the ability of E2F1 to interact with pRb in order to successfully induce apoptosis. To further address this, we examined whether TGFb could induce association between endogenous E2F1 and pRb using co-immunoprecipitation studies. As shown in Figure 5c , TGFb treatment indeed promotes the association between E2F1 and pRb. Altogether, these results indicate that pRb-E2F binding is required for TGFb to induce apoptosis and that this association is induced by TGFb itself, strongly supporting the fact that the pRb-E2F1 protein complex has a role downstream of TGFb-mediated cell signaling, leading to apoptosis.
TGFb induces formation of a transcriptionally active complex between pRb/E2F1 and the acetyltransferase P/CAF onto pro-apoptotic gene promoters. Given the classical model of E2F regulation, which implies that E2F1 must be in its unbound form in order to activate transcription, this raised the question as to how E2F1 activates these proapoptotic genes in response to TGFb while remaining in its seemingly transcriptionally repressive pRb-E2F complex. Thus, we assessed whether TGFb could in fact recruit positive regulators of transcription to the pRb-E2F1 complex. As TGFb may activate gene transcription through histone acetyltransferases, including p300/CBP (cAMP-response elementbinding protein (CREB)-binding protein) and P/CAF (p300/CBPassociated factor), 31 we screened for the presence of these histone acetyltransferases in E2F1 and pRb immunoprecipitates in untreated versus TGFb-treated cells. Interestingly, as shown 7 and Smac/DIABLO mRNA levels were measured by real-time qPCR analysis. Results are normalized to GAPDH and show the mean ± S.D., expressed as relative to levels observed in untreated cells (set to 1). (c) HuH7 cells untreated or treated with TGFb (100 pM) were subjected to immunoprecipitation (IP) with the specified antibodies followed by western blotting (WB) to assess levels of associated E2F1 and pRb in Figure 6a , we found that TGFb strongly promotes the association of both E2F1 and pRb to the acetyltransferase P/CAF. Moreover, these complexes appear to be P/CAF specific as we could not detect any association between pRb-E2F1 and p300/CBP.
We then addressed whether P/CAF is required for the activation of E2F1-responsive pro-apoptotic genes and induction of apoptosis in response to TGFb. Loss of P/CAF expression by RNA interference dramatically reduced the TGFb pro-apoptotic effect in these cells (Figure 6b) . Moreover, the TGFb-induced expression levels of Caspase 7 and Smac/DIABLO were notably reduced when P/CAF expression was silenced by siRNA ( Figure 6c) . As caspases require post-translational activation to become catalytically active and Figure 6 TGFb induces formation of a transcriptionally active complex between pRb/E2F1 and the acetyltransferase P/CAF, onto pro-apoptotic gene promoters. (a) Untreated and TGFb-treated HuH7 cells were subjected to immunoprecipitation (IP) with the specified antibodies followed by western blotting (WB) to assess levels of P/ CAF or CBP/p300 and associated E2F1 and pRb. (b and c) HuH7 cells were transiently transfected with siRNA against P/CAF or a control non-silencing siRNA and treated with TGFb (100 pM) for 24 h. mediate cell death, 32 we investigated whether the loss of TGFb-induced caspase expression due to P/CAF knockdown was followed by a decrease in caspase activity. As shown in Figure 6e (left panel), blocking P/CAF expression severely impaired TGFb-mediated Caspase 3/7 activation. This effect was similar to what was observed when E2F1 expression was silenced (Figure 6e, right panel) . By 48 h, loss of either P/CAF or E2F1 expression nearly completely abolished TGFbinduced caspase activation. Collectively, these findings support a critical role for P/CAF downstream of TGFb in the E2F1-dependent activation of pro-apoptotic genes and the mediation of programmed cell death.
To then assess the functional relevance of the TGFbinduced pRb-E2F1-P/CAF complex in regulating TGFb transcriptional responses, we performed chromatin immunoprecipitation assays to determine whether this complex is recruited to the pro-apoptotic target gene promoters in response to TGFb. We examined the promoters of the TGFband E2F1-responsive pro-apoptotic genes identified above. Interestingly, as shown in Figure 6f , TGFb treatment markedly induced recruitment of all three partners (E2F1, pRb, and P/CAF) to the p73, Apaf1, Caspase 7, and Smac/DIABLO gene promoters, concurring with the TGFb-mediated increase in the mRNA levels of these pro-apoptotic genes and activation of the apoptotic program. These results highlight the E2F1-pRb-P/CAF pathway as a major signaling axis leading to apoptosis downstream of TGFb in normal and cancer cells.
Discussion
Although various apoptotic mediators and signaling pathways have been implicated in TGFb-mediated apoptosis, most of these regulatory mechanisms appear to be cell type-dependent or tissue-specific. 4 This study defines a novel process of gene activation by the TGFb-E2F1 signaling axis, and highlights the pRb-E2F1-P/CAF pathway as a wide-ranging and critical mediator of the TGFb apoptotic program in multiple target tissues.
We identified a number of key pro-apoptotic TGFb target genes that trigger the intrinsic apoptosis pathway through the induction of E2F1. Although these genes are functionally interrelated, our results imply that TGFb regulates the intrinsic apoptosis pathway at multiple levels, consistent with the strong pro-apoptotic effect of this growth factor in its target tissues. However, we do not exclude the possibility that induction of other targets (or pathways) might also contribute to E2F1-dependent TGFb-mediated cell death. Importantly, these results are corroborated using the E2F1 knockout mouse model, demonstrating that the TGFb-E2F1 signaling pathway mediates TGFb-induced cell death not only in a diseased state but in a normal cell setting as well.
Although it is well-established that E2F1 activity is intimately controlled through association with pRb, the precise mechanisms of this regulation are somewhat contradictory. The prevailing view holds that the pRb-E2F1 complex acts as a repressor of E2F target genes. 12 Accordingly, disruption of this pRb-E2F1 complex is required to release free E2F1 in order to induce transcription of its target genes. Paradoxically, pRb-E2F1 complexes were recently shown to transcriptionally activate pro-apoptotic genes in response to DNA damage through recruitment of a histone acetyltransferase to the pRb-E2F1 complex. 33 Interestingly, our results also challenge this dogma, and support a non-classic transcriptionally active pRb-E2F1 regulatory complex, as we show here that the pRb-E2F1 complex can also recruit an actyltransferase (P/CAF) to activate transcription of pro-apototic genes in response to TGFb. Indeed, analysis with dominant-negative E2F1 mutants revealed that, in fact, pRb binding to E2F1 is required for TGFb-mediated apoptosis.
Our results also indicate that TGFb rapidly increases E2F1 protein levels, acting at the post-translational level. Interestingly, several lines of evidence have demonstrated that the E2Fs are often regulated by post-translational modifications such as phosphorylation, 34 acetylation, 35 and by the ubiquitin-proteasome pathways. 36 Binding of pRb to E2F1 protects E2F1 from ubiquitination and proteolytic degradation, 37 thereby increasing its stability. As TGFb maintains pRb in a hypophosphorylated form, causing E2F1 to remain bound to pRb and suppressing activation of E2F1-responsive cell-cycle regulatory genes, 38 it is likely that the TGFb effect on E2F1 protein levels is mediated through induction of pRb-E2F1 association, revealing a new level of E2F1 regulation.
Moreover, the association of P/CAF to E2F1 may also contribute to the increased stability of E2F1 protein levels in response to TGFb, as P/CAF also binds and acetylates E2F1, prolonging its half-life. In fact, E2F1 acetylation by P/CAF has three functional effects on E2F1 activity: increased proteinhalf life, DNA-binding ability, and activation potential. 35 Thus, P/CAF binding to E2F1 in response to TGFb may in fact have multiple functional consequences, affecting not only E2F1 stability but its transcriptional-activating capability as well.
Additional post-translational modifications of E2F1 and/or pRb may also contribute to the formation of the pro-apoptotic complex. Notably, pRb holds a second alternate E2F1-specific binding site that does not interfere with E2F1's transactivation domain. 39 It is interesting to consider, then, whether TGFb could somehow induce pRb and E2F1 to assume this alternate conformation. If so, this conformation should also allow for recruitment of P/CAF, which we have demonstrated here to be required for TGFb to activate E2F1-dependent pro-apoptotic target genes. The coordinated recruitment of E2F1, pRb, and P/CAF to these pro-apoptotic gene promoters suggests the potential formation of a transcriptionally active pRb-E2F1 complex, which mediates the regulation of TGFb pro-apoptotic targets. Taken together, these results strongly support a pro-apoptotic role for the E2F1 pathway downstream of TGFb and provide a potential mechanism for the activation of E2F1-responsive pro-apoptotic genes in response to TGFb.
It is interesting to consider that TGFb tumor-suppressive effects might utilize the functional interplay among the E2F family members, which affects E2F activity. It is well-established that TGFb prevents cell-cycle progression, causing G1 arrest, by up-regulating expression of Cdk (cyclin-dependent kinase) inhibitors and by inhibiting both cdc25a (cell division cycle 25 homolog A) 40 and c-myc 41 by means of Smad-E2F4/5-pocket protein repressor complexes. The rapid surge in E2F1 that we observe in response to TGFb may thus effectively initiate the TGFb apoptotic program, without affecting cell cycle, as TGFb maintains transcriptional repression of factors required for S-phase entry through the other E2F family members. Moreover, E2F4, in complex with pRb or p107, is capable of binding to E2F-binding sites on the E2F1 promoter, leading to its repression after 4 h of TGFb treatment. 28 Thus, it is conceivable that TGFb treatment leads to increased levels of E2F1, triggering the activation of pro-apoptotic genes. Subsequently, in addition to directly inhibiting cell-cycle regulatory genes, E2F4 may repress E2F1 levels following longer stimulation with TGFb, further preventing cell-cycle progression.
The present work delineates a novel process of gene activation by the TGFb-E2F1 signaling axis and supports a role for the E2F family as potent co-transducers of TGFb signals. Combined with previous studies from our lab and others, these findings highlight the crucial role for the E2F family in regulating TGFb tumor-suppressive effects and we propose the following model of E2F tumor-suppressive action downstream of TGFb ( 
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(3) The current study demonstrates that TGFb can also recruit E2F1 into transcriptionally active pRb-E2F1-P/ CAF complexes, increasing the expression of multiple pro-apoptotic target genes and inducing programmed cell death.
It is interesting to note that the E2F family acts via distinct pathways to regulate specific genes, yet all toward a global action of tumor suppression. We can thus consider the E2F family as 'super-mediators' of TGFb tumor-suppressive effects. A better understanding of the mechanisms by which both TGFb and E2F1 exert their tumor-suppressive roles may prove useful for the development of novel therapeutic strategies aimed at restoring the apoptotic or tumor-suppressive response of the E2Fs in human cancer. Viability assays. Cells were seeded in triplicate in 96-well plates, at 10 000 cells/100 ml in medium supplemented with 2% FBS, and in the presence or absence of 100 pM TGFb. Mitochondrial viability was determined by MTT colorimetric assay. Briefly, following 24-72 h of TGFb treatment, cells were incubated with 1 mg/ml MTT solution (Sigma-Aldrich) in the culture media for 2 h. Formazan crystals were solubilized overnight in 50% dimethyl formamide, 20% SDS, pH 4.7, and the absorbance of each well was measured at 570 nm using a microplate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA). Alternatively, cell viability was determined by the fluorescent calcein-AM method. Briefly, following 4-24 h of TGFb treatment, original culture medium was replaced with serum-free medium containing 2 mg/ml calcein-AM (BD Biosciences, San Diego, CA, USA) for 60 min at 37 1C. Cells were then washed twice with PBS and the fluorescence of each well was monitored from the bottom of the wells at excitation and emission wavelengths of 485 and 520 nm, respectively, using a FLUOstar Optima microplate reader (BMG Labtech, Ortenberg, Germany).
RNA isolation and real-time quantitative PCR. Total RNA was isolated from cell lines using TRIzol reagent (Invitrogen) and reverse transcribed using random hexamers and M-MLV Reverse Transcriptase (Invitrogen), as per the manufacturer's instructions. Subsequently, real-time qPCR was carried out using SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA, USA) in a RotorGene 6000 PCR detection system (Corbett Life Science, Montreal Biotech Inc., Kirkland, QC, Canada). The conditions for qPCR were as follows: 95 1C for 30 s, 40 cycles of 95 1C for 5 s, and 60 1C for 20 s. Primer sequences are listed in Table 1 . Where indicated, some cDNAs were amplified for 30 cycles instead and amplified products were analyzed by DNA gel electrophoresis.
Immunoblotting and immunoprecipitation. Cells were lysed in cold RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 1 mM EDTA), containing 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl fluoride, 5 mg/ml aprotinin, 2 mg/ml leupeptin, and 1 mg/ml pepstatin. TGFb-mediated cell death requires pRb-E2F1-P/CAF J Korah et al
